Physician profile
Eric G Delay
NPI 1366460412
$3,623.70
in general payments reported to CMS, 2019-2025
41 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $471 · 2021: $458 · 2022: $558 · 2023: $446 · 2024: $519 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Entertainment: $12.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.62 |
| Entertainment | $12.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,038.40 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $393.52 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $308.42 | 2020-2025 | Synthroid, Qulipta |
| Glaxosmithkline, LLC. | $264.64 | 2020-2025 | Shingrix, Bexsero, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.45 | 2020-2025 | Jardiance |
| Pfizer INC. | $149.75 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $103.12 | 2022-2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $93.84 | 2019-2022 | |
| Corium, LLC | $77.28 | 2022-2023 | Adlarity |
| Merck Sharp & Dohme LLC | $75.04 | 2020-2023 | Vaxneuvance, Pneumovax 23, Vaxelis |
| Lilly USA, LLC | $73.41 | 2020-2022 | |
| Amarin Pharma, INC. | $72.43 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $71.00 | 2020-2024 | Xarelto |
| Esperion Therapeutics, INC. | $55.62 | 2020-2021 | |
| Allergan, INC. | $49.68 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Delay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.